The emergence of an ethical duty to disclose genetic research results: international perspectives

被引:199
作者
Knoppers, Bartha Maria
Joly, Yann
Simard, Jacques
Durocher, Francine
机构
[1] Univ Montreal, Ctr Rech Droit Publ, Montreal, PQ H3C 3J7, Canada
[2] Univ Laval, Dept Anat Physiol, CHUQ, Res Ctr,CHUL, Laval, PQ, Canada
基金
加拿大健康研究院;
关键词
duty to re-contact; right to know; right not to know; communication of results; genetic research; bioethics;
D O I
10.1038/sj.ejhg.5201690
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The last decade has witnessed the emergence of international ethics guidelines discussing the importance of disclosing global and also, in certain circumstances, individual genetic research results to participants. This discussion is all the more important considering the advent of pharmacogenomics and the increasing incidence of 'translational' genetic research in the post-genomic era. We surveyed both the literature and the ethical guidelines using selective keywords. We then analyzed our data using a qualitative method approach and singled out countries or policies that were representative of certain positions. From our findings, we conclude that at the international level, there now exists an ethical duty to return individual genetic research results subject to the existence of proof of validity, significance and benefit. Even where these criteria are met, the right of the research participant not to know also has to be taken into consideration. The existence of an ethical duty to return individual genetic research results begs several other questions: Who should have the responsibility of disclosing such results and when? To whom should the results be disclosed? How? Finally, will this ethical 'imperative' become a legally recognized duty as well?
引用
收藏
页码:1170 / 1178
页数:9
相关论文
共 33 条
  • [1] *AM SOC HUM GEN, 1988, DNA BANK DNA AN POIN
  • [2] Elements of informed consent for pharmacogenetic research; perspective of the pharmacogenetics working group
    Anderson D.C.
    Gomez-Mancilla B.
    Spear B.B.
    Barnes D.M.
    Cheeseman K.
    Shaw P.M.
    Friedman J.
    McCarthy A.
    Brazell C.
    Ray S.C.
    McHale D.
    Hashimoto L.
    Sandbrink R.
    Watson M.L.
    Salerno R.A.
    Cohen N.
    Lister C.E.
    [J]. The Pharmacogenomics Journal, 2002, 2 (5) : 284 - 292
  • [3] [Anonymous], 1997, INT C HARM TECHN REQ
  • [4] [Anonymous], 1991, INT GUID ETH REV EP
  • [5] Banks T M, 2000, Sask Law Rev, V63, P539
  • [6] Reporting genetic results in research studies: Summary and recommendations of an NHLBI working group
    Bookman, EB
    Langehorne, AA
    Eckfeldt, JH
    Glass, KC
    Jarvik, GP
    Klag, M
    Koski, G
    Motulsky, A
    Wilfond, B
    Manolio, TA
    Fabsitz, RR
    Luepker, RV
    [J]. AMERICAN JOURNAL OF MEDICAL GENETICS PART A, 2006, 140A (10) : 1033 - 1040
  • [7] Centers for Medicare & Medicaid Services Department of Health and Human Services, 2003, FED REGISTER, V68, P3640
  • [8] Clarke A, 2001, INT J PHARM MED, V15, P89
  • [9] Consortium on Pharmacogenetics, 2002, ETH REG ISS RES CLIN
  • [10] Council for International Organizations of Medical Sciences, 2002, INT ETH GUID BIOM RE